Member Info for Karlvonwise

Hi Geraidus, What likely happened is that a large institutional investor (a "Whale") wanted to buy a huge chunk of Verici privately. UBS "hoovered up" those shares on May 7th to facilitate the deal, which triggered the 7.8% reporting rule.

Then UBS moved the shares into a private account , which emptied UBS account which triggered the 2nd RNS.

So, like me there ate other whales out there hoovering up those shares but doing it discreetly so not to push the share price

Best wishes Karlvonwise

I believe there maybe a whale out there hoovering uo the shares , with the same expectations as me.

Most of these shares are actually buys , especially the 2.5 million

Kind Regards Karlvonwise x

At time of writing there was 2 trades. One was. A sell for 75000 shares @ 0.454. And the other was fa buy for a small amount of shares @ 0.50 .

The reason I know the 75000 shares was a buy is because it belongs to me :)

Best wishes all Karlvonwise

@mikemine as long as it makes you feel better , then thats quality 😀

Best wishes Karlvonwise

@Mikemine I genuinely think your time may be better spent making a cup of tea than writing to LSE about “misrepresentation.”

At least the tea has a guaranteed return and probably tastes better too 🙂

Best wishes,

Karlvonwise

@mikemine I think they’ve probably assembled the team they need now.

The commercial side has already done an excellent job, and with Keith Gilliard now onboard, they have someone with direct industry experience who likely understands how to get past the gatekeepers and reach the real decision-makers within transplant centres.

As for another fundraise, that remains a possibility rather than a certainty. A lot will depend on how quickly adoption and revenues continue to grow over the next few quarters.

If people are interested, I can also look into some of the other recruits and post a breakdown of their backgrounds, experience, and areas of expertise.

I’ve already done some research on two of them so far.

Keith Gilliard previously worked at CareDx

before joining Verici Dx. That is probably the most savy relevant recruitment VRCI has made recently because CareDx

is one of the dominant names in transplant diagnostics in the US. His background appears to include:

transplant diagnostics sales,

transplant-centre relationships,

commercialization experience in organ transplant pathways,

and broader healthcare/pharma experience at:

Novartis

Bristol Myers Squibb

OrganOx

As much as it’s tempting to analyse Keith Gilliard’s career in detail and infer a lot from it, the reality is that the data simply isn’t strong enough to draw firm conclusions.

We can be cautiously positive about his appointment and what it might signal in terms of commercial intent, but it’s important to stay grounded in what is actually known rather than what we might assume.

He only joined in April, so while he may already have started opening doors and contributing to early relationship-building, it’s still very early days. In a transplant diagnostics market — where sales cycles are long, adoption is slow, and clinical relationships take time to embed — it’s unlikely he has had enough time to materially shift sales performance yet.

Best Wishes Karlvonwise

I’ve spent the day analyzing the trade logs, and there’s a clear divergence between the ‘reported’ sentiment and the volume reality.

​I’ve made two buys yesterday (including a final 22k at 0.455p right before the close). Interestingly, both were marked as ‘Sell*’ on the LSE tape despite being confirmed buys. This suggests that much of the 2 million+ volume we’ve seen today is actually mid-price accumulation being misidentified by the algorithm.

​The logic is simple: if that 2 million volume consisted of genuine sells, we would be looking at a collapsing share price. Instead, we’re seeing a solid floor being built at 0.45p.

​With the Full Year Audit due by the end of this month, it looks like someone is ‘hoovering’ up every available share without moving the price—yet. They’ve recognized that the 32% growth and the Keith Gilliard recruitment have fundamentally changed the risk/reward here.

​Positioned at x amount of shares and happy to wait for the official numbers to drop.

Snagged a final 22k at 0.455p at 16:28. Naturally took that price without hesitation. If you track the trades today, the pressure is clearly on the buy side, although mafked as sells . Great to see the conviction building as we head into a big month for the company

I’ll leave the 'AI' paranoia to a certain fabourite friend of mine—I’ll stick to the RNS filings and the clinical data.Since he finished casting doubt on my previous plays, let's address the only real, documented risk at Verici:

The Cash Runway.As of the last update, Verici’s runway extends into H2 2026 (supported by the £6.35m raise). We are in a race against time to hit cash-flow positivity. But look at the fuel we just added to the engine: The 32% Velocity: 392 tests in Q1 isn't just a number; it’s proof of a 32% quarter-on-quarter growth trajectory. At $2,650 (£2,100) per test via Medicare, the gap between 'burn' and 'earn' is closing rapidly.

You don't hire a Senior Director from the industry leader (CareDx) unless you are moving for the kill. In medical sales, it’s about who you know. Gilliard has the Rolodex to bypass the typical 18-month 'evaluation' phase at US centers and move straight to protocol adoption.While we focus on the runway, CareDx and Natera are circling each other in a $96m legal battle (probably appeals to come). Their cfDNA tests are reactive—they detect cell death (damage control). Verici’s RNA-based tests (Clarava and Tutivia) are proactive, catching the immune response before the damage is done. Yes, there is a risk of a loan or small dilution in H2 to bridge the gap. But I’d rather back a company diluting for Commercial Expansion with a CareDx heavy-hitter at the helm than a 'zombie' company with no sales.If the competitors want to 'circle' for our assets, they’ll find the price going up every time Gilliard adds another transplant center to our 20% US coverage. I'm happy with my position at 0.459p. See you at the May Audit x

For my critical friend @ Stockscapital : since you like to dispel my experience in AFC and Mast (QDE), then allow me to share my research in VRCI and its competitors for you to cast doubt on it:

While you’re stuck on the QDE ‘back story,’ I’m looking at the Future of Transplantation.

Verici’s main competitors, CareDx and Natera, have spent years in a ‘war of attrition’ in the courts, with CareDx recently hit by a $96 million jury award for false advertising. They are distracted by litigation and ‘damage control’ for their own products.

The science also favors Verici. The rivals’ tests (cfDNA) are reactive—they wait for the organ to start dying before they trigger an alert. Verici is the only player covering the full patient journey:

Clarava (Pre-Op): Identifies risk before the first incision. No one else has this.

Tutivia (Post-Op): Uses RNA expression to catch the immune response before the organ takes damage.

This is why the recruitment of Keith Gilliard (who came directly from CareDx) is the pivot point. He didn’t jump ship from an industry leader to join a ‘pump’—he joined because he knows the competitors are tied up in legal drama and Verici has the ‘proactive’ product that surgeons actually want.

I’ll stick with my buy this morning at 0.459p, as well as my previous buys and the man with the Rolodex. I’m happy to let you keep casting doubt while the 32% growth turns into a market breakout.

@Stockscapital : I would be suspicious of that AI generated post. These boards have unfortunately become full of them.

Bit of clanger in that particular ChatGPT copy and paste to refer to QDE to try and pump this. Look at that company's back story, the long term chart, and fact it is now suspended

It’s easy to cry ‘AI’ when you don’t have an answer for the actual facts.

Let’s look at the ‘back story’ you mentioned: Quantum Data Energy (QDE) requested a temporary suspension on May 1st for a very specific, documented reason—their auditor, Crowe UK LLP, resigned unexpectedly on April 29th (RNS 2880C). Under FCA rules, you cannot trade if you miss the audit deadline. That is a regulatory hurdle, not a failure of the business model or their fund-raising.

In fact, if you’d read the news from April 23rd and 29th, you’d see they actually confirmed an amendment to their equity raise and commenced construction on the Bordesley 5 MW project. They are raising money and building assets while dealing with a technical audit delay.

I’m not ‘pumping’ anything—I’m identifying a pattern. Like AFC Energy at Dunsfold, companies often face ‘turbulence’ before the personnel they recruit (like Keith Gilliard here at Verici) propel them to the next level.

I’d be more suspicious of posters who ignore RNS filings to push a negative narrative than those who actually do the research. I’ll stick with the 32% growth and the ex-CareDx leadership. Good luck with the guesswork.

I will now refer to my next post, to help you out as you seem to like to live in the past

@Mikemine and the board — Just added 60,000 shares at 0.459p this morning. I’m now heavily positioned because I recognize the pattern playing out here.

In small caps, a 'proven product' is only half the battle. The real value is unlocked when the company pivots to Selective Recruitment—bringing in the people who don't just know 'what' to sell, but 'who' to call.

We’ve seen this script before:

AFC Energy (The Dunsfold Success): They had the tech at 3p, but it sat idle until they got the right people in. Those people did the unplanned roadshows, hit the pavement, and navigated the 'unseen' industry hurdles. The result? A rocket from 3p to 89p.

MAST (now QDE): They were retailing at 0.20p, struggling for air. They brought in a specialist CEO with the specific expertise to raise funds and realize the enterprise's value. He didn't change the product; he changed the access to capital and execution.

Verici is at this exact junction.

The product is proven (32% growth, Medicare locked in). But the recruitment of Keith Gilliard (ex-CareDx) is the masterstroke. In the transplant world, it is 100% about specialist contacts. By hiring a heavyweight from the industry leader, Verici has essentially bought the 'Rolodex' of the competition.

Gilliard knows the surgeons, he knows the procurement officers, and most importantly, he knows exactly where the competition is failing.

I’m betting on the 'Who,' not just the 'What.' The science got us to 32% growth; Gilliard and the specialist recruitment will be what propels us to the analyst target of 2.90p+. Holding tight for the May Audit results

The sells this morning are actually buys

@Mikemine — My own thoughts on the current action:

I’m starting to believe that when you see this level of strategic "static" (the 1-share trades and mid-price walking), it’s a clear sign of an investor trying to suppress the SP to manufacture a better entry or average down before the next leg up.

The real "North Star" here isn't the daily noise—it's the TR-1 trail from UBS. Having a Tier-1 global powerhouse constantly active on the register provides a level of institutional validation you just don't see on most AIM stocks of this size.

With the 32% volume growth confirmed in Q1 and the results looming, I’m looking past the manipulation. If the "Goliaths" are playing games to get cheaper shares, I’m happy to follow their lead and build my position while they’re still keeping the lid on it. Fundamentals always win out in the end.

.

Those tiny trades are just 'noise' meant to manipulate the computer's price triggers; they don't reflect the actual 0.47p valuation. The million-share trade is nothing more than a standard exit—just an investor pulling their capital, which is a common move in any strategy.

A few of those sells are buys including mine or not a large amount of shares .

All the best Karlvonwise

Spot on Mikemine: It's frustrating to see high-conviction buys show up as sells just because of where they sit in the spread. The automated reporting is definitely flawed. Either way, the volume is there, and with UBS on the register, the 'direction of travel' seems clear regardless of how the MMs label it!

My buy is actually showing as a sell .

Increased to X amount of shares today. If it's good enough for UBS, it's good enough for me. That 32% sales growth in Q1 shows the platform is finally scaling. Ready for the moonshot. 🚀

These are my own thoughts ; my own money , your capital is at risk if you using my comments as your conviction.

All the best Karlvonwise

One of the world’s most sophisticated financial institutions has decided that Verici Dx is worth owning nearly 8% of .yet the board remains quiet ?